ProFound Insights, ProFound Impact:
Risk Assessment Reimagined
Previously Aired - June 21, 2022
Discover the power of ProFound AI® Risk, the latest addition to iCAD’s breast AI suite and the world’s first clinical decision support tool that provides an accurate, short-term breast cancer risk estimation that is truly personalized for each woman, based only on her mammogram. Featured panelists:
Watch as we sit down with leading experts who will discuss the significant impact of ProFound AI Risk, including distinguished researchers from the Karolinska Institutet and clinicians who are using it in daily practice.
Learn how only iCAD’s breast AI suite offers a single, triple-threat solution for cancer detection, density assessment and risk evaluation that provides a more holistic approach to personalized screening and superior cancer detection.
Radiologie am Theater, Paderborn, Germany
University of Michigan Health-West, Wyoming, MI
Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
Sed ut perspiciatis unde omnis iste natus error sit voluptatem!
Nemo enim ipsam voluptatem quia voluptas sit odit aut fugit!
Ut enim ad minima veniam, quis nostrum exercitationem ullam!